<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Pipeline | Novascope BioChips</title>
<meta name="description" content="Novascope BioChips Pipeline — 98% accuracy in sepsis detection, NfL R²=0.97-0.99 vs SIMOA, biomarker portfolio across infectious disease, neurodegeneration, oncology.">
<meta property="og:title" content="Pipeline | Novascope BioChips">
<meta property="og:description" content="Novascope BioChips Pipeline — 98% accuracy in sepsis detection, NfL R²=0.97-0.99 vs SIMOA, biomarker portfolio across infectious disease, neurodegeneration, oncology.">
<meta property="og:type" content="website">
<meta property="og:site_name" content="Novascope BioChips">
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=DM+Mono:wght@400;500&family=DM+Sans:wght@400;500;600;700&family=Playfair+Display:wght@400;600;700;800&display=swap" rel="stylesheet">
<style>
:root{--t:#0D9488;--t2:#0B7C73;--t3:#14B8A6;--gold:#C8A44E;--gold2:#D4B65E;--d1:#0F1923;--d2:#1A2836;--d3:#243447;--bg:#FAFBFC;--bg2:#F1F5F9;--txt:#1E293B;--txt2:#475569;--txt3:#94A3B8;--w:#FFFFFF;--r:#EF4444;--g:#22C55E;--fd:'Playfair Display',Georgia,serif;--fb:'DM Sans',system-ui,sans-serif;--fm:'DM Mono',monospace;--e:cubic-bezier(.4,0,.2,1);--sh:0 1px 3px rgba(0,0,0,.1),0 1px 2px rgba(0,0,0,.06);--sh2:0 4px 6px rgba(0,0,0,.07),0 2px 4px rgba(0,0,0,.06);--sh3:0 10px 15px rgba(0,0,0,.1),0 4px 6px rgba(0,0,0,.05);--sh4:0 20px 25px rgba(0,0,0,.1),0 10px 10px rgba(0,0,0,.04);--r1:8px;--r2:12px;--r3:16px;--r4:24px}
*,*::before,*::after{box-sizing:border-box;margin:0;padding:0}
html{scroll-behavior:smooth;font-size:16px;-webkit-text-size-adjust:100%}
body{font-family:var(--fb);color:var(--txt);background:var(--bg);line-height:1.7;overflow-x:hidden;-webkit-font-smoothing:antialiased}
img{max-width:100%;height:auto;display:block}
a{color:var(--t);text-decoration:none;transition:color .2s var(--e)}
a:hover{color:var(--t2)}
h1,h2,h3,h4,h5,h6{font-family:var(--fd);font-weight:700;line-height:1.2;color:var(--d1)}
h1{font-size:clamp(2rem,5vw,3.5rem);letter-spacing:-0.02em}
h2{font-size:clamp(1.75rem,4vw,2.75rem);letter-spacing:-0.01em}
h3{font-size:clamp(1.25rem,2.5vw,1.75rem)}
h4{font-size:clamp(1.1rem,2vw,1.35rem)}
p{margin-bottom:1rem;color:var(--txt2)}
.mono{font-family:var(--fm)}
.accent{color:var(--t)}
.gold{color:var(--gold)}
.container{max-width:1200px;margin:0 auto;padding:0 24px}
.container-lg{max-width:1400px;margin:0 auto;padding:0 24px}

/* Navigation */
.nav{position:fixed;top:0;left:0;right:0;z-index:1000;background:rgba(15,25,35,.97);backdrop-filter:blur(12px);border-bottom:1px solid rgba(255,255,255,.06);transition:all .3s var(--e)}
.nav-inner{max-width:1400px;margin:0 auto;padding:0 24px;display:flex;align-items:center;justify-content:space-between;height:72px}
.nav-logo{height:36px;width:auto}
.nav-links{display:flex;gap:4px;align-items:center}
.nav-link{color:rgba(255,255,255,.7);font-size:.875rem;font-weight:500;padding:8px 14px;border-radius:var(--r1);transition:all .2s var(--e);white-space:nowrap;font-family:var(--fb)}
.nav-link:hover,.nav-link.active{color:var(--w);background:rgba(255,255,255,.08)}
.nav-link.active{color:var(--t3)}
.nav-cta{background:var(--t)!important;color:var(--w)!important;font-weight:600;padding:8px 20px!important;border-radius:var(--r4)!important}
.nav-cta:hover{background:var(--t2)!important;transform:translateY(-1px)}
.hamburger{display:none;flex-direction:column;gap:5px;background:none;border:none;cursor:pointer;padding:8px}
.hamburger span{display:block;width:22px;height:2px;background:var(--w);border-radius:2px;transition:all .3s var(--e)}
.mobile-menu{display:none;position:fixed;top:72px;left:0;right:0;background:rgba(15,25,35,.98);backdrop-filter:blur(12px);padding:16px 24px 24px;border-bottom:1px solid rgba(255,255,255,.06)}
.mobile-menu.open{display:block}
.mobile-menu .nav-link{display:block;padding:12px 16px;font-size:1rem}

/* Hero sections */
.hero{position:relative;padding:160px 0 100px;overflow:hidden;background:linear-gradient(135deg,var(--d1) 0%,var(--d2) 50%,var(--d3) 100%)}
.hero-grid{position:absolute;inset:0;background-image:radial-gradient(rgba(13,148,136,.12) 1px,transparent 1px);background-size:32px 32px;opacity:.6}
.hero-glow{position:absolute;top:-30%;right:-20%;width:60%;height:120%;background:radial-gradient(ellipse,rgba(13,148,136,.08) 0%,transparent 70%);pointer-events:none}
.hero h1{color:var(--w);margin-bottom:16px}
.hero p{color:rgba(255,255,255,.7);font-size:1.125rem;max-width:640px}
.hero .label{display:inline-block;font-family:var(--fm);font-size:.75rem;letter-spacing:.15em;text-transform:uppercase;color:var(--t3);margin-bottom:16px;padding:6px 16px;background:rgba(13,148,136,.1);border:1px solid rgba(13,148,136,.2);border-radius:var(--r4)}

/* Sections */
.section{padding:100px 0}
.section-dark{background:linear-gradient(180deg,var(--d1),var(--d2));color:var(--w)}
.section-dark h2,.section-dark h3,.section-dark h4{color:var(--w)}
.section-dark p{color:rgba(255,255,255,.7)}
.section-alt{background:var(--bg2)}
.section-label{display:inline-block;font-family:var(--fm);font-size:.7rem;letter-spacing:.2em;text-transform:uppercase;color:var(--t);margin-bottom:12px;font-weight:600}
.section-head{margin-bottom:48px}
.section-head p{font-size:1.125rem;max-width:700px;margin-top:12px}

/* Cards */
.card{background:var(--w);border-radius:var(--r3);padding:32px;border:1px solid rgba(0,0,0,.06);transition:all .3s var(--e)}
.card:hover{transform:translateY(-4px);box-shadow:var(--sh3);border-color:rgba(13,148,136,.15)}
.card-dark{background:rgba(255,255,255,.04);border-color:rgba(255,255,255,.08)}
.card-dark:hover{background:rgba(255,255,255,.07);border-color:rgba(13,148,136,.3)}
.card-icon{width:48px;height:48px;border-radius:var(--r2);background:rgba(13,148,136,.08);display:flex;align-items:center;justify-content:center;margin-bottom:16px}
.card-icon svg{width:24px;height:24px;fill:none;stroke:var(--t);stroke-width:1.5;stroke-linecap:round;stroke-linejoin:round}

/* Grid layouts */
.grid-2{display:grid;grid-template-columns:repeat(2,1fr);gap:32px}
.grid-3{display:grid;grid-template-columns:repeat(3,1fr);gap:32px}
.grid-4{display:grid;grid-template-columns:repeat(4,1fr);gap:24px}
.grid-6{display:grid;grid-template-columns:repeat(3,1fr);gap:24px}

/* Metrics strip */
.metrics{display:flex;justify-content:center;gap:48px;padding:32px 0;flex-wrap:wrap}
.metric{text-align:center}
.metric-val{font-family:var(--fm);font-size:2rem;font-weight:700;color:var(--t3)}
.metric-label{font-size:.8rem;color:rgba(255,255,255,.5);margin-top:4px;letter-spacing:.05em}

/* Trust badges */
.badges{display:flex;justify-content:center;gap:24px;flex-wrap:wrap;padding:24px 0}
.badge{display:flex;align-items:center;gap:8px;padding:8px 16px;background:rgba(255,255,255,.05);border:1px solid rgba(255,255,255,.08);border-radius:var(--r4);font-size:.8rem;color:rgba(255,255,255,.6);font-family:var(--fm)}
.badge svg{width:16px;height:16px;stroke:var(--t3);fill:none;stroke-width:2}

/* Buttons */
.btn{display:inline-flex;align-items:center;gap:8px;padding:12px 28px;border-radius:var(--r4);font-weight:600;font-size:.9rem;transition:all .3s var(--e);cursor:pointer;border:none;font-family:var(--fb)}
.btn-primary{background:var(--t);color:var(--w)}
.btn-primary:hover{background:var(--t2);color:var(--w);transform:translateY(-2px);box-shadow:0 4px 12px rgba(13,148,136,.3)}
.btn-outline{border:1.5px solid var(--t);color:var(--t);background:transparent}
.btn-outline:hover{background:var(--t);color:var(--w)}
.btn-dark{border:1.5px solid rgba(255,255,255,.2);color:rgba(255,255,255,.8);background:transparent}
.btn-dark:hover{border-color:var(--t3);color:var(--t3)}

/* Tables */
.tbl-wrap{overflow-x:auto;border-radius:var(--r2);border:1px solid rgba(0,0,0,.08)}
.tbl{width:100%;border-collapse:collapse;font-size:.85rem}
.tbl th{background:var(--d1);color:var(--w);padding:12px 16px;text-align:left;font-weight:600;font-family:var(--fb);white-space:nowrap}
.tbl td{padding:10px 16px;border-bottom:1px solid rgba(0,0,0,.06);vertical-align:top}
.tbl tr:nth-child(even){background:var(--bg2)}
.tbl-dark th{background:var(--t)}
.tbl-dark td{border-color:rgba(255,255,255,.06);color:rgba(255,255,255,.8)}
.tbl-dark tr:nth-child(even){background:rgba(255,255,255,.03)}
.tbl .highlight{background:rgba(13,148,136,.06);font-weight:600}

/* Progress bars */
.progress-wrap{margin-bottom:16px}
.progress-label{display:flex;justify-content:space-between;font-size:.85rem;margin-bottom:6px}
.progress-bar{height:8px;background:rgba(0,0,0,.06);border-radius:4px;overflow:hidden}
.progress-fill{height:100%;background:linear-gradient(90deg,var(--t),var(--t3));border-radius:4px;width:0;transition:width 1.5s var(--e)}

/* Animations */
.fo{opacity:0;transform:translateY(28px);transition:opacity .7s var(--e),transform .7s var(--e)}
.fo.vis{opacity:1;transform:translateY(0)}
.fo-d1{transition-delay:.1s}.fo-d2{transition-delay:.2s}.fo-d3{transition-delay:.3s}.fo-d4{transition-delay:.4s}.fo-d5{transition-delay:.5s}

/* Image containers */
.img-frame{border-radius:var(--r2);overflow:hidden;border:1px solid rgba(0,0,0,.06);background:var(--bg2)}
.img-frame img{width:100%;display:block}
.img-caption{font-size:.75rem;color:var(--txt3);padding:8px 12px;background:var(--bg2);font-family:var(--fm)}

/* Expandable bios */
.team-card{text-align:center;padding:24px}
.team-photo{width:120px;height:120px;border-radius:50%;object-fit:cover;margin:0 auto 16px;border:3px solid var(--bg2)}
.team-name{font-family:var(--fd);font-size:1.1rem;font-weight:700;color:var(--d1)}
.team-title{font-size:.8rem;color:var(--t);font-weight:600;margin:4px 0 8px}
.team-bio{font-size:.8rem;color:var(--txt2);line-height:1.6;max-height:0;overflow:hidden;transition:max-height .5s var(--e)}
.team-card.expanded .team-bio{max-height:300px}
.team-toggle{font-size:.75rem;color:var(--t);cursor:pointer;margin-top:8px;font-weight:600;border:none;background:none;font-family:var(--fb)}

/* Timeline */
.timeline{position:relative;padding-left:32px}
.timeline::before{content:'';position:absolute;left:12px;top:0;bottom:0;width:2px;background:linear-gradient(180deg,var(--t),var(--t3))}
.tl-item{position:relative;margin-bottom:32px}
.tl-item::before{content:'';position:absolute;left:-24px;top:4px;width:12px;height:12px;border-radius:50%;background:var(--t);border:3px solid var(--bg)}
.tl-year{font-family:var(--fm);font-size:.75rem;color:var(--t);font-weight:700;letter-spacing:.1em}
.tl-title{font-weight:700;margin:4px 0}
.tl-desc{font-size:.85rem;color:var(--txt2)}

/* Footer */
.footer{background:var(--d1);color:rgba(255,255,255,.6);padding:60px 0 0}
.footer-grid{display:grid;grid-template-columns:2fr 1fr 1fr 1fr;gap:40px;padding-bottom:40px;border-bottom:1px solid rgba(255,255,255,.08)}
.footer h4{color:var(--w);font-size:.9rem;margin-bottom:16px}
.footer a{color:rgba(255,255,255,.5);font-size:.85rem}
.footer a:hover{color:var(--t3)}
.footer-links{list-style:none;display:flex;flex-direction:column;gap:8px}
.footer-bottom{padding:24px 0;font-size:.75rem;color:rgba(255,255,255,.35);line-height:1.8}
.footer-legal{margin-top:16px;padding-top:16px;border-top:1px solid rgba(255,255,255,.06);font-size:.7rem;line-height:1.8;color:rgba(255,255,255,.25)}
.footer-logo{height:28px;margin-bottom:16px;opacity:.7}

/* Six Pillars Hex Grid */
.pillars-grid{display:grid;grid-template-columns:repeat(3,1fr);gap:20px;max-width:900px;margin:0 auto}
.pillar-card{position:relative;padding:28px 20px;text-align:center;background:rgba(255,255,255,.03);border:1px solid rgba(255,255,255,.08);border-radius:var(--r3);transition:all .3s var(--e)}
.pillar-card:hover{border-color:var(--t3);background:rgba(13,148,136,.05);transform:translateY(-4px)}
.pillar-icon{width:56px;height:56px;margin:0 auto 12px;border-radius:var(--r2);background:rgba(13,148,136,.1);display:flex;align-items:center;justify-content:center}
.pillar-icon svg{width:28px;height:28px;stroke:var(--t3);fill:none;stroke-width:1.5}
.pillar-name{font-family:var(--fm);font-size:.85rem;font-weight:700;color:var(--t3);margin-bottom:4px}
.pillar-desc{font-size:.78rem;color:rgba(255,255,255,.5);line-height:1.5}

/* IHC Gallery */
.ihc-gallery{display:grid;grid-template-columns:repeat(auto-fit,minmax(200px,1fr));gap:12px}
.ihc-item{border-radius:var(--r2);overflow:hidden;border:1px solid rgba(0,0,0,.08)}
.ihc-item img{width:100%;aspect-ratio:1;object-fit:cover}
.ihc-label{font-size:.7rem;padding:6px 8px;text-align:center;background:var(--bg2);font-family:var(--fm);color:var(--txt2)}

/* Responsive */
@media(max-width:1024px){
.nav-links{display:none}.hamburger{display:flex}
.grid-4{grid-template-columns:repeat(2,1fr)}
.footer-grid{grid-template-columns:1fr 1fr}
}
@media(max-width:768px){
.grid-2,.grid-3,.grid-6{grid-template-columns:1fr}
.pillars-grid{grid-template-columns:repeat(2,1fr)}
.metrics{gap:24px}
.hero{padding:120px 0 60px}
.section{padding:60px 0}
.footer-grid{grid-template-columns:1fr}
}
@media(max-width:480px){
.pillars-grid{grid-template-columns:1fr}
.grid-4{grid-template-columns:1fr}
.metrics{flex-direction:column;gap:16px}
}
@media(prefers-reduced-motion:reduce){.fo{opacity:1;transform:none;transition:none}}
</style>
<noscript><style>.fo{opacity:1;transform:none}</style></noscript>
</head>
<body>
<nav class="nav" role="navigation" aria-label="Main navigation">
<div class="nav-inner">
<a href="index.html"><img id="nav-logo" class="nav-logo" alt="Novascope BioChips" src=""></a>
<div class="nav-links"><a href="index.html" class="nav-link">Home</a><a href="about.html" class="nav-link">About</a><a href="technology.html" class="nav-link">Technology</a><a href="pipeline.html" class="nav-link active">Pipeline</a><a href="solutions.html" class="nav-link">Solutions</a><a href="investors.html" class="nav-link">Investors</a><a href="news.html" class="nav-link">News</a><a href="partners.html" class="nav-link">Partners</a><a href="contact.html" class="nav-link nav-cta">Contact</a></div>
<button class="hamburger" aria-label="Menu" onclick="document.querySelector('.mobile-menu').classList.toggle('open')">
<span></span><span></span><span></span>
</button>
</div>
<div class="mobile-menu"><a href="index.html" class="nav-link">Home</a><a href="about.html" class="nav-link">About</a><a href="technology.html" class="nav-link">Technology</a><a href="pipeline.html" class="nav-link active">Pipeline</a><a href="solutions.html" class="nav-link">Solutions</a><a href="investors.html" class="nav-link">Investors</a><a href="news.html" class="nav-link">News</a><a href="partners.html" class="nav-link">Partners</a><a href="contact.html" class="nav-link">Contact</a></div>
</nav>

<!-- Hero -->
<section class="hero">
<div class="hero-grid"></div>
<div class="hero-glow"></div>
<div class="container" style="position:relative;z-index:1">
<div class="label fo">Pipeline &amp; Clinical Evidence</div>
<h1 class="fo fo-d1">Clinical Validation<br><span style="color:var(--t3)">Breakthrough</span></h1>
<p class="fo fo-d2">Technology de-risked, performance proven. Third-party validated clinical data from IRB-approved protocols at Chang Gung Memorial Hospital.</p>
</div>
</section>

<!-- Biomarker Portfolio -->
<section class="section">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label">Portfolio</div>
<h2>Biomarker Portfolio Under Development</h2>
</div>
<div class="fo fo-d1 tbl-wrap">
<table class="tbl">
<thead>
<tr><th>Field</th><th>Infectious Disease</th><th>Neurodegeneration</th><th>Oncology</th><th>Veterinary</th></tr>
</thead>
<tbody>
<tr><td><strong>Probe Type</strong></td><td>NA (Nucleic Acid)</td><td>Ab &amp; NA</td><td>NA</td><td>Ab &amp; NA</td></tr>
<tr><td><strong>Biomarker Probes</strong></td>
<td style="font-size:.8rem">E. faecium, A. baumannii, K. pneumoniae, E. coli, E. faecalis, P. aeruginosa, S. aureus + AMR genes (CTX-M, IMP, KPC, mcr-1a, mecA/C, VIM, NDM, OXA-48)</td>
<td style="font-size:.8rem">NfL, p-Tau 181, p-Tau 217, p-Tau 231, GFAP, A&beta; 42/40, TDP-43, &alpha;-Synuclein, S100B, UCH-L1</td>
<td style="font-size:.8rem">EGFR (168 actionable mutations), liquid biopsy panel</td>
<td style="font-size:.8rem">Veterinary pathogen panel, companion animal diagnostics</td>
</tr>
<tr><td><strong>Status</strong></td>
<td><span style="background:var(--g);color:var(--w);padding:2px 8px;border-radius:10px;font-size:.7rem;font-weight:600">Validated</span></td>
<td><span style="background:var(--gold);color:var(--w);padding:2px 8px;border-radius:10px;font-size:.7rem;font-weight:600">In Development</span></td>
<td><span style="background:var(--txt3);color:var(--w);padding:2px 8px;border-radius:10px;font-size:.7rem;font-weight:600">Pipeline</span></td>
<td><span style="background:var(--txt3);color:var(--w);padding:2px 8px;border-radius:10px;font-size:.7rem;font-weight:600">Pipeline</span></td>
</tr>
</tbody>
</table>
</div>
<div class="fo fo-d2" style="margin-top:24px">
<div class="img-frame">
<img data-img="BIOMARKER_FLOW" alt="Biomarker development flow">
<div class="img-caption">Biomarker portfolio development workflow across four therapeutic areas</div>
</div>
</div>
</div>
</section>

<!-- Sepsis -->
<section class="section section-dark" id="sepsis">
<div class="container">
<div class="section-head fo">
<div class="section-label" style="color:var(--t3)">Lead Indication</div>
<h2>Sepsis: Direct-from-Blood Bacterial Detection</h2>
<p style="max-width:700px">In third-party clinical validation at Chang Gung Memorial Hospital (CGMH), the NS01 platform achieved breakthrough performance on the hardest clinical challenge &mdash; detecting pathogens directly from uncultured whole blood.</p>
</div>

<!-- Clinical Results -->
<div class="grid-2 fo fo-d1" style="gap:48px;align-items:start">
<div>
<h3 style="margin-bottom:24px">Clinical Validation Results</h3>

<!-- Progress bars -->
<div class="progress-wrap">
<div class="progress-label"><span style="color:var(--w)">Overall Accuracy</span><span style="color:var(--t3);font-family:var(--fm);font-weight:700">98%</span></div>
<div class="progress-bar" style="background:rgba(255,255,255,.1)"><div class="progress-fill" data-width="98%"></div></div>
</div>
<div class="progress-wrap">
<div class="progress-label"><span style="color:var(--w)">Sensitivity</span><span style="color:var(--t3);font-family:var(--fm);font-weight:700">97%</span></div>
<div class="progress-bar" style="background:rgba(255,255,255,.1)"><div class="progress-fill" data-width="97%"></div></div>
</div>
<div class="progress-wrap">
<div class="progress-label"><span style="color:var(--w)">Specificity</span><span style="color:var(--t3);font-family:var(--fm);font-weight:700">100%</span></div>
<div class="progress-bar" style="background:rgba(255,255,255,.1)"><div class="progress-fill" data-width="100%"></div></div>
</div>
<div class="progress-wrap">
<div class="progress-label"><span style="color:var(--w)">PPV</span><span style="color:var(--t3);font-family:var(--fm);font-weight:700">100%</span></div>
<div class="progress-bar" style="background:rgba(255,255,255,.1)"><div class="progress-fill" data-width="100%"></div></div>
</div>
<div class="progress-wrap">
<div class="progress-label"><span style="color:var(--w)">NPV</span><span style="color:var(--t3);font-family:var(--fm);font-weight:700">91%</span></div>
<div class="progress-bar" style="background:rgba(255,255,255,.1)"><div class="progress-fill" data-width="91%"></div></div>
</div>

<p style="font-size:.75rem;margin-top:16px;color:rgba(255,255,255,.4)">Non-cultured clinical whole blood samples. 88 clinical samples, LinKou CGMH hospital. Single-center, IRB-approved protocol. Turnaround: &lt;1h vs 2&ndash;5 days culture.</p>

<!-- Confusion Matrices -->
<div style="margin-top:32px">
<h4 style="margin-bottom:16px;font-size:.9rem">Third-Party Validation &mdash; Confusion Matrices</h4>
<div class="grid-2" style="gap:16px">
<div>
<div style="font-family:var(--fm);font-size:.7rem;color:var(--t3);margin-bottom:8px">NON-CULTURED BLOOD</div>
<table class="tbl tbl-dark" style="font-size:.8rem">
<tr><th></th><th>Actual +</th><th>Actual &minus;</th></tr>
<tr><td><strong>Chip +</strong></td><td style="color:var(--g);font-weight:700">TP = 33</td><td>FP = 0</td></tr>
<tr><td><strong>Chip &minus;</strong></td><td>FN = 1</td><td style="color:var(--g);font-weight:700">TN = 10</td></tr>
</table>
</div>
<div>
<div style="font-family:var(--fm);font-size:.7rem;color:var(--gold);margin-bottom:8px">POST-CULTURE BLOOD</div>
<table class="tbl tbl-dark" style="font-size:.8rem">
<tr><th></th><th>Actual +</th><th>Actual &minus;</th></tr>
<tr><td><strong>Chip +</strong></td><td style="color:var(--g);font-weight:700">TP = 33</td><td>FP = 1</td></tr>
<tr><td><strong>Chip &minus;</strong></td><td>FN = 1</td><td style="color:var(--g);font-weight:700">TN = 9</td></tr>
</table>
</div>
</div>
</div>
</div>

<div>
<div class="img-frame" style="border-color:rgba(255,255,255,.1)">
<img data-img="SEPSIS" alt="Sepsis detection chip results">
<div class="img-caption" style="background:var(--d2);color:rgba(255,255,255,.5)">Direct-from-whole-blood detection results</div>
</div>
<div class="img-frame" style="margin-top:16px;border-color:rgba(255,255,255,.1)">
<img data-img="CLINICAL_BREAKTHROUGH" alt="Clinical validation breakthrough">
<div class="img-caption" style="background:var(--d2);color:rgba(255,255,255,.5)">Clinical validation breakthrough: 98% accuracy in sepsis detection</div>
</div>

<!-- Key stats -->
<div style="display:grid;grid-template-columns:1fr 1fr;gap:12px;margin-top:16px">
<div class="card card-dark" style="padding:16px;text-align:center">
<div style="font-family:var(--fm);font-size:1.5rem;font-weight:700;color:#EF4444">10&sup2;</div>
<div style="font-size:.7rem;color:rgba(255,255,255,.5)">cfu/mL LOD</div>
</div>
<div class="card card-dark" style="padding:16px;text-align:center">
<div style="font-family:var(--fm);font-size:1.5rem;font-weight:700;color:#EF4444">1,000&times;</div>
<div style="font-size:.7rem;color:rgba(255,255,255,.5)">vs BioFire sensitivity</div>
</div>
</div>
</div>
</div>
</div>
</section>

<!-- Alzheimer's -->
<section class="section" id="alzheimers">
<div class="container">
<div class="section-head fo">
<div class="section-label">Neurodegeneration</div>
<h2>Alzheimer&rsquo;s Disease: Head-to-Head vs SIMOA</h2>
<p style="max-width:700px">Across three independent batches testing NfL in clinical samples, Novascope achieved R&sup2; values of 0.96&ndash;0.97 against the Quanterix SIMOA platform (SIMOA self-correlation: 0.98&ndash;0.99). Matching the $300,000 gold standard on a desktop platform.</p>
</div>

<div class="grid-2 fo fo-d1" style="align-items:start;gap:48px">
<div>
<h4 style="margin-bottom:16px">NfL Correlation Data</h4>
<div class="img-frame">
<img data-img="CORRELATION" alt="NfL correlation Novascope vs SIMOA">
<div class="img-caption">NfL cross-platform correlation: Novascope vs Quanterix SIMOA &mdash; R&sup2; = 0.97&ndash;0.99</div>
</div>
<div class="img-frame" style="margin-top:16px">
<img data-img="AD" alt="Alzheimer's biomarker panel">
<div class="img-caption">Alzheimer&rsquo;s disease biomarker detection panel</div>
</div>
</div>
<div>
<h4 style="margin-bottom:16px">Neurodegeneration Biomarker Panel</h4>
<div class="tbl-wrap">
<table class="tbl" style="font-size:.8rem">
<tr><th>Biomarker</th><th>Status</th><th>Application</th></tr>
<tr class="highlight"><td><strong>NfL</strong></td><td style="color:var(--g);font-weight:600">Validated (R&sup2;=0.97&ndash;0.99)</td><td>Pan-neurodegeneration</td></tr>
<tr><td><strong>p-Tau 217</strong></td><td style="color:var(--gold);font-weight:600">In Development</td><td>AD-specific &mdash; key differentiator</td></tr>
<tr><td><strong>p-Tau 231</strong></td><td style="color:var(--gold);font-weight:600">In Development</td><td>AD staging</td></tr>
<tr><td>p-Tau 181</td><td style="color:var(--gold)">In Development</td><td>AD screening</td></tr>
<tr><td>GFAP</td><td style="color:var(--gold)">In Development</td><td>Astrocyte activation</td></tr>
<tr><td>A&beta; 42/40</td><td style="color:var(--txt3)">Pipeline</td><td>Amyloid pathology ratio</td></tr>
<tr><td>TDP-43</td><td style="color:var(--txt3)">Pipeline</td><td>FTD, ALS</td></tr>
<tr><td>&alpha;-Synuclein</td><td style="color:var(--txt3)">Pipeline</td><td>Parkinson&rsquo;s, LBD</td></tr>
<tr><td>S100B</td><td style="color:var(--txt3)">Pipeline</td><td>Brain injury marker</td></tr>
<tr><td>UCH-L1</td><td style="color:var(--txt3)">Pipeline</td><td>Traumatic brain injury</td></tr>
</table>
</div>

<div style="margin-top:24px;padding:20px;background:rgba(139,92,246,.05);border:1px solid rgba(139,92,246,.15);border-radius:var(--r2)">
<h4 style="color:#8B5CF6;font-size:.9rem;margin-bottom:8px">Market Catalyst: AD Drug Revolution</h4>
<p style="font-size:.85rem">Lecanemab (Leqembi) at $26,500/year creates mandatory biomarker screening demand. Current PET/CSF testing: $500&ndash;$1,250 at reference labs only. 6M+ Americans with AD need affordable, decentralized biomarker testing. Novascope target: ~$200/test at a local clinic.</p>
</div>
</div>
</div>

<!-- AD Pathway & IHC Gallery -->
<div class="fo fo-d2" style="margin-top:48px">
<h4 style="margin-bottom:16px">AD Biomarker Pathway</h4>
<div class="img-frame">
<img data-img="AD_PATHWAY" alt="Alzheimer's disease biomarker pathway">
<div class="img-caption">Alzheimer&rsquo;s disease biomarker pathway &mdash; from blood to brain tissue validation</div>
</div>
</div>

<div class="fo fo-d3" style="margin-top:48px">
<h4 style="margin-bottom:16px">IHC Brain Tissue Gallery &mdash; Antibody Validation</h4>
<p style="font-size:.85rem;margin-bottom:16px;color:var(--txt2)">The ultimate specificity validation: testing neurological antibodies against human brain tissue from Alzheimer&rsquo;s disease patients using immunohistochemistry &mdash; the gold standard. Independent researchers confirmed staining patterns match published references.</p>
<div class="ihc-gallery">
<div class="ihc-item"><img data-img="IHC_PTAU217" alt="IHC pTau-217 staining"><div class="ihc-label">p-Tau 217</div></div>
<div class="ihc-item"><img data-img="IHC_NFL" alt="IHC NfL staining"><div class="ihc-label">NfL</div></div>
<div class="ihc-item"><img data-img="IHC_PTAU181" alt="IHC pTau-181 staining"><div class="ihc-label">p-Tau 181</div></div>
<div class="ihc-item"><img data-img="IHC_PTAU231" alt="IHC pTau-231 staining"><div class="ihc-label">p-Tau 231</div></div>
<div class="ihc-item"><img data-img="IHC_GFAP" alt="IHC GFAP staining"><div class="ihc-label">GFAP</div></div>
<div class="ihc-item"><img data-img="BRAIN_PTAU217" alt="Brain tissue pTau-217"><div class="ihc-label">Brain p-Tau 217</div></div>
<div class="ihc-item"><img data-img="BRAIN_NFL" alt="Brain tissue NfL"><div class="ihc-label">Brain NfL</div></div>
</div>
</div>
</div>
</section>

<!-- Competitive IVD Landscape -->
<section class="section section-alt">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label">Competitive Landscape</div>
<h2>Competitive IVD Landscape (Nucleic Acid)</h2>
</div>
<div class="fo fo-d1 tbl-wrap">
<table class="tbl" style="font-size:.78rem">
<thead>
<tr><th>Specification</th><th>BioFire BCID2</th><th>T2 Bacteria</th><th>Roche Eplex</th><th>Vivalytic (BOSCH)</th><th style="background:var(--t)">NOVASCOPE</th></tr>
</thead>
<tbody>
<tr><td><strong>Technology</strong></td><td>Multiplex PCR</td><td>T2MR</td><td>AC Voltammetry</td><td>Multiplex PCR</td><td class="highlight"><strong>FET / BioIC</strong></td></tr>
<tr><td><strong>Specimen</strong></td><td>Positive blood culture</td><td>Whole blood</td><td>Positive blood culture</td><td>Various</td><td class="highlight"><strong>Whole blood (direct)</strong></td></tr>
<tr><td><strong>Pathogens</strong></td><td>43</td><td>6</td><td>55</td><td>Variable</td><td class="highlight"><strong>7 + 10 AMR genes</strong></td></tr>
<tr><td><strong>Reaction time</strong></td><td>~1 hour</td><td>3&ndash;5 hours</td><td>~1.5 hours</td><td>~30 min</td><td class="highlight"><strong>&lt;60 min</strong></td></tr>
<tr><td><strong>Incubation req.</strong></td><td>12&ndash;24h culture</td><td>None</td><td>12&ndash;24h culture</td><td>None</td><td class="highlight"><strong>None</strong></td></tr>
<tr><td><strong>Total testing</strong></td><td>13&ndash;25 hours</td><td>3&ndash;5 hours</td><td>13&ndash;25 hours</td><td>~30 min</td><td class="highlight"><strong>&lt;60 min</strong></td></tr>
<tr><td><strong>LOD</strong></td><td>5&times;10&sup5; cfu/mL</td><td>Variable</td><td>Variable</td><td>Variable</td><td class="highlight"><strong>10&sup2; cfu/mL</strong></td></tr>
<tr><td><strong>AMR genes</strong></td><td>10</td><td>No</td><td>4</td><td>Variable</td><td class="highlight"><strong>10</strong></td></tr>
<tr><td><strong>2024 Revenue</strong></td><td>&euro;1,494M</td><td>$8.3M</td><td>~$50M+</td><td>N/A</td><td class="highlight">Pre-revenue</td></tr>
</tbody>
</table>
</div>
<p style="font-size:.7rem;color:var(--txt3);margin-top:12px;text-align:center">Competitor data from publicly available sources. Novascope data from internal clinical validation. Source: Company filings, press releases.</p>

<div class="fo fo-d2" style="margin-top:32px">
<div class="grid-2" style="gap:24px">
<div class="img-frame"><img data-img="LANDSCAPE" alt="Competitive IVD landscape visual"><div class="img-caption">Competitive landscape &mdash; pathogen detection technologies</div></div>
<div class="img-frame"><img data-img="COMPETITOR" alt="Competitor comparison"><div class="img-caption">Technology comparison across IVD platforms</div></div>
</div>
</div>
</div>
</section>

<!-- Clinical Biobank -->
<section class="section section-dark">
<div class="container">
<div class="grid-2 fo" style="align-items:center;gap:48px">
<div>
<div class="section-label" style="color:var(--t3)">Biobank</div>
<h2>Clinical Biobank &amp; WGS Library</h2>
<p style="margin-top:16px">Our most underappreciated asset: a proprietary biorepository transferred from Chang Gung Memorial Hospital spanning ~30 years of clinical isolates. This is a multi-year, multi-million-dollar data asset that competitors cannot replicate.</p>

<div class="counter-group" style="display:grid;grid-template-columns:repeat(2,1fr);gap:16px;margin-top:24px">
<div class="card card-dark" style="padding:16px;text-align:center">
<div style="font-family:var(--fm);font-size:2rem;font-weight:700;color:var(--t3)"><span class="count" data-count="700" data-suffix="+">0</span></div>
<div style="font-size:.75rem;color:rgba(255,255,255,.5)">Bacterial Isolates</div>
</div>
<div class="card card-dark" style="padding:16px;text-align:center">
<div style="font-family:var(--fm);font-size:2rem;font-weight:700;color:var(--t3)"><span class="count" data-count="394">0</span></div>
<div style="font-size:.75rem;color:rgba(255,255,255,.5)">Bacterial Species</div>
</div>
<div class="card card-dark" style="padding:16px;text-align:center">
<div style="font-family:var(--fm);font-size:2rem;font-weight:700;color:var(--t3)"><span class="count" data-count="206">0</span></div>
<div style="font-size:.75rem;color:rgba(255,255,255,.5)">WGS-Ready</div>
</div>
<div class="card card-dark" style="padding:16px;text-align:center">
<div style="font-family:var(--fm);font-size:2rem;font-weight:700;color:var(--t3)"><span class="count" data-count="494">0</span></div>
<div style="font-size:.75rem;color:rgba(255,255,255,.5)">DNA Extracted</div>
</div>
</div>

<p style="font-size:.8rem;margin-top:16px">Additionally maintains PET-validated, clinically characterized Alzheimer&rsquo;s disease samples for neurodegeneration assay development.</p>
</div>
<div>
<div class="img-frame" style="border-color:rgba(255,255,255,.1)">
<img data-img="GINSENG" alt="Biobank collection">
<div class="img-caption" style="background:var(--d2);color:rgba(255,255,255,.5)">Proprietary biorepository from CGMH &mdash; spanning ~30 years of clinical isolates</div>
</div>
</div>
</div>
</div>
</section>

<!-- Regulatory Roadmap -->
<section class="section">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label">Regulatory</div>
<h2>Regulatory Roadmap 2025&ndash;2028</h2>
<p style="margin:12px auto 0;max-width:650px">Strategic dual-track approach: securing Class I registration while advancing Class II clinical validation for sepsis diagnostics.</p>
</div>

<!-- Timeline SVG -->
<div class="fo fo-d1" style="margin-bottom:40px">
<svg viewBox="0 0 900 280" style="width:100%;max-width:900px;margin:0 auto;display:block" xmlns="http://www.w3.org/2000/svg">
<!-- Timeline axis -->
<line x1="50" y1="140" x2="850" y2="140" stroke="#0D9488" stroke-width="2"/>

<!-- Year markers -->
<circle cx="100" cy="140" r="8" fill="#0D9488"/><text x="100" y="170" text-anchor="middle" fill="var(--txt)" font-family="DM Mono,monospace" font-size="11" font-weight="700">2025</text>
<circle cx="300" cy="140" r="8" fill="#0D9488"/><text x="300" y="170" text-anchor="middle" fill="var(--txt)" font-family="DM Mono,monospace" font-size="11" font-weight="700">2026</text>
<circle cx="500" cy="140" r="8" fill="#C8A44E"/><text x="500" y="170" text-anchor="middle" fill="var(--txt)" font-family="DM Mono,monospace" font-size="11" font-weight="700">2027</text>
<circle cx="700" cy="140" r="8" fill="#C8A44E"/><text x="700" y="170" text-anchor="middle" fill="var(--txt)" font-family="DM Mono,monospace" font-size="11" font-weight="700">2028</text>

<!-- 2025: Platform Foundation -->
<rect x="50" y="40" width="200" height="70" rx="8" fill="rgba(13,148,136,.06)" stroke="rgba(13,148,136,.3)" stroke-width="1"/>
<text x="150" y="60" text-anchor="middle" fill="#0D9488" font-family="DM Mono,monospace" font-size="8" font-weight="700">PLATFORM FOUNDATION</text>
<text x="150" y="75" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">3rd-party verification</text>
<text x="150" y="88" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">E. coli chip finalized</text>
<text x="150" y="101" text-anchor="middle" fill="var(--g)" font-family="DM Sans,sans-serif" font-size="8" font-weight="600">COMPLETED</text>

<!-- 2026: Dual-Track -->
<rect x="225" y="40" width="200" height="70" rx="8" fill="rgba(13,148,136,.06)" stroke="rgba(13,148,136,.3)" stroke-width="1"/>
<text x="325" y="60" text-anchor="middle" fill="#0D9488" font-family="DM Mono,monospace" font-size="8" font-weight="700">DUAL-TRACK EXECUTION</text>
<text x="325" y="75" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">Class I TFDA registration</text>
<text x="325" y="88" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">Class II preclinical verification</text>
<text x="325" y="101" text-anchor="middle" fill="var(--gold)" font-family="DM Sans,sans-serif" font-size="8" font-weight="600">IN PROGRESS</text>

<!-- Track A: Class I -->
<rect x="200" y="190" width="250" height="40" rx="6" fill="rgba(13,148,136,.08)" stroke="rgba(13,148,136,.2)" stroke-width="1"/>
<text x="325" y="205" text-anchor="middle" fill="#0D9488" font-family="DM Mono,monospace" font-size="8" font-weight="700">Track A: Class I (TFDA)</text>
<text x="325" y="220" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="7">QMS &rarr; Registration &rarr; Market Entry</text>

<!-- 2027-2028: Clinical & Launch -->
<rect x="425" y="40" width="200" height="70" rx="8" fill="rgba(200,164,78,.06)" stroke="rgba(200,164,78,.3)" stroke-width="1"/>
<text x="525" y="60" text-anchor="middle" fill="#C8A44E" font-family="DM Mono,monospace" font-size="8" font-weight="700">CLINICAL TRIALS</text>
<text x="525" y="75" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">Clinical validation studies</text>
<text x="525" y="88" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">FDA submission preparation</text>

<rect x="625" y="40" width="200" height="70" rx="8" fill="rgba(200,164,78,.06)" stroke="rgba(200,164,78,.3)" stroke-width="1"/>
<text x="725" y="60" text-anchor="middle" fill="#C8A44E" font-family="DM Mono,monospace" font-size="8" font-weight="700">FIRST REGULATED PRODUCT</text>
<text x="725" y="75" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">TFDA Class II approval</text>
<text x="725" y="88" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="8">US FDA pathway</text>

<!-- Track B: Class II -->
<rect x="350" y="190" width="400" height="40" rx="6" fill="rgba(200,164,78,.08)" stroke="rgba(200,164,78,.2)" stroke-width="1"/>
<text x="550" y="205" text-anchor="middle" fill="#C8A44E" font-family="DM Mono,monospace" font-size="8" font-weight="700">Track B: Class II (TFDA &rarr; US FDA)</text>
<text x="550" y="220" text-anchor="middle" fill="var(--txt2)" font-family="DM Sans,sans-serif" font-size="7">Preclinical Spec &rarr; Clinical Trials &rarr; Regulatory Approval &rarr; Launch</text>
</svg>
</div>

<div class="fo fo-d2">
<div class="grid-2" style="gap:24px">
<div class="img-frame">
<img data-img="ROADMAP_BOARD" alt="Regulatory development roadmap">
<div class="img-caption">Regulatory development roadmap &mdash; dual-track strategy for Class I &amp; Class II</div>
</div>
<div class="img-frame">
<img data-img="DUALTRACK" alt="Dual-track regulatory execution">
<div class="img-caption">2026 dual-track regulatory strategy execution timeline</div>
</div>
</div>
</div>

<p style="font-size:.7rem;color:var(--txt3);margin-top:16px;text-align:center;font-style:italic">Products referenced are for Research Use Only (RUO). Not for use in diagnostic procedures unless otherwise specified. Clinical data from IRB-approved research protocols.</p>
</div>
</section>

<footer class="footer">
<div class="container">
<div class="footer-grid">
<div>
<img id="ft-logo" class="footer-logo" alt="Novascope" src="">
<p style="font-size:.85rem;max-width:360px">Where Silicon Meets Biology. Novascope BioChips is building the semiconductor platform that transforms diagnostics.</p>
</div>
<div>
<h4>Company</h4>
<ul class="footer-links">
<li><a href="about.html">About Us</a></li>
<li><a href="technology.html">Technology</a></li>
<li><a href="pipeline.html">Pipeline</a></li>
<li><a href="solutions.html">Solutions</a></li>
</ul>
</div>
<div>
<h4>Resources</h4>
<ul class="footer-links">
<li><a href="investors.html">Investors</a></li>
<li><a href="news.html">News</a></li>
<li><a href="partners.html">Partners</a></li>
<li><a href="contact.html">Contact</a></li>
</ul>
</div>
<div>
<h4>Legal</h4>
<ul class="footer-links">
<li><a href="#" onclick="document.getElementById('privacy-modal').style.display='flex';return false">Privacy Policy</a></li>
<li><a href="#" onclick="document.getElementById('terms-modal').style.display='flex';return false">Terms of Use</a></li>
<li><a href="investors.html#disclaimers">Forward-Looking Statements</a></li>
</ul>
</div>
</div>
<div class="footer-bottom">
<p>&copy; 2026 Novascope BioChips Inc. All rights reserved. Delaware, USA.</p>
<p style="margin-top:4px">FDA Establishment Registration: Registered facility &bull; ISO 13485: Certified quality management system &bull; Patent Notice: Protected by one or more patents</p>
<p style="margin-top:4px">NovaCHIP&trade;, NovaLINK&trade;, NovaBIO&trade;, NovaKIT&trade;, NovaAI&trade;, NovaCRO&trade;, and NVDFlow&trade; are trademarks of Novascope BioChips Inc.</p>
<div class="footer-legal">
<p><strong>Forward-Looking Statements:</strong> This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties, including but not limited to: regulatory approvals, clinical trial outcomes, market adoption, competition, intellectual property, manufacturing scale-up, and general economic conditions.</p>
<p style="margin-top:8px"><strong>No Solicitation:</strong> Nothing on this website constitutes an offer to sell or solicitation of an offer to buy any securities of Novascope BioChips Inc. Any such offer or solicitation will be made only by means of a confidential private placement memorandum and only to qualified investors in compliance with applicable securities laws.</p>
<p style="margin-top:8px"><strong>Research Use Only:</strong> Products referenced herein are for Research Use Only (RUO). Not for use in diagnostic procedures unless otherwise specified. Clinical data presented are from IRB-approved research protocols and do not represent claims of regulatory clearance or approval.</p>
</div>
</div>
</div>
</footer>

<!-- Privacy Modal -->
<div id="privacy-modal" style="display:none;position:fixed;inset:0;z-index:9999;background:rgba(0,0,0,.6);align-items:center;justify-content:center" onclick="if(event.target===this)this.style.display='none'">
<div style="background:var(--w);border-radius:var(--r3);padding:40px;max-width:600px;max-height:80vh;overflow-y:auto;margin:24px">
<h3>Privacy Policy</h3>
<p style="margin-top:16px;font-size:.85rem">Novascope BioChips Inc. respects your privacy. We collect only information voluntarily provided through contact forms. We do not sell, trade, or otherwise transfer your personal information to third parties. This site uses cookies for analytics purposes only. For inquiries regarding our privacy practices, contact: <a href="mailto:privacy@novascopedx.com">privacy@novascopedx.com</a></p>
<button class="btn btn-primary" style="margin-top:20px" onclick="this.closest('div[id]').style.display='none'">Close</button>
</div>
</div>

<!-- Terms Modal -->
<div id="terms-modal" style="display:none;position:fixed;inset:0;z-index:9999;background:rgba(0,0,0,.6);align-items:center;justify-content:center" onclick="if(event.target===this)this.style.display='none'">
<div style="background:var(--w);border-radius:var(--r3);padding:40px;max-width:600px;max-height:80vh;overflow-y:auto;margin:24px">
<h3>Terms of Use</h3>
<p style="margin-top:16px;font-size:.85rem">By accessing this website, you agree to these terms. All content is provided for informational purposes only and does not constitute investment advice, an offer to sell, or solicitation of an offer to buy any securities. All intellectual property rights are reserved by Novascope BioChips Inc. Unauthorized reproduction or distribution of any content is prohibited. Information may be changed or updated without notice. Novascope makes no warranties regarding the accuracy or completeness of information presented.</p>
<button class="btn btn-primary" style="margin-top:20px" onclick="this.closest('div[id]').style.display='none'">Close</button>
</div>
</div>
<script src="images.js"></script>
<script>
// Image mapping
(function(){
var I=window.__IMG||{};
var maps={
'nav-logo':I.LOGO_H,'ft-logo':I.LOGO_H
};
// Add page-specific mappings from data-img attributes
document.querySelectorAll('[data-img]').forEach(function(el){
var key=el.getAttribute('data-img');
if(I[key])el.src=I[key];
});
for(var id in maps){
var el=document.getElementById(id);
if(el&&maps[id])el.src=maps[id];
}
})();

// Scroll animations
var obs=new IntersectionObserver(function(entries){
entries.forEach(function(e){
if(e.isIntersecting){e.target.classList.add('vis');obs.unobserve(e.target)}
});
},{threshold:0.1,rootMargin:'0px 0px -40px 0px'});
document.querySelectorAll('.fo').forEach(function(el){obs.observe(el)});

// Animated counters
var counterObs=new IntersectionObserver(function(entries){
entries.forEach(function(e){
if(e.isIntersecting){
e.target.querySelectorAll('.count').forEach(function(el){
var target=parseFloat(el.getAttribute('data-count'));
var prefix=el.getAttribute('data-prefix')||'';
var suffix=el.getAttribute('data-suffix')||'';
var isDecimal=target%1!==0;
var duration=1500;var startTime=null;
function animate(ts){
if(!startTime)startTime=ts;
var progress=Math.min((ts-startTime)/duration,1);
var eased=1-Math.pow(1-progress,3);
var current=target*eased;
el.textContent=prefix+(isDecimal?current.toFixed(1):Math.round(current))+(progress<1?'':suffix);
if(progress<1)requestAnimationFrame(animate);
}
requestAnimationFrame(animate);
});
counterObs.unobserve(e.target);
}
});
},{threshold:0.3});
document.querySelectorAll('.counter-group').forEach(function(el){counterObs.observe(el)});

// Progress bar animations
var progObs=new IntersectionObserver(function(entries){
entries.forEach(function(e){
if(e.isIntersecting){
e.target.querySelectorAll('.progress-fill').forEach(function(bar){
bar.style.width=bar.getAttribute('data-width');
});
progObs.unobserve(e.target);
}
});
},{threshold:0.3});
document.querySelectorAll('.progress-wrap').forEach(function(el){progObs.observe(el)});

// Team bio toggle
document.querySelectorAll('.team-toggle').forEach(function(btn){
btn.addEventListener('click',function(){
var card=this.closest('.team-card');
card.classList.toggle('expanded');
this.textContent=card.classList.contains('expanded')?'Show less':'Read more';
});
});

// Mobile hamburger
document.querySelector('.hamburger')&&document.querySelector('.hamburger').addEventListener('click',function(){
document.querySelector('.mobile-menu').classList.toggle('open');
});
</script>
</body>
</html>